

# CITATION REPORT

List of articles citing

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

DOI: 10.1186/s13075-019-1910-2

Arthritis Research and Therapy, 2019, 21, 122.

**Source:** <https://exaly.com/paper-pdf/73140743/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim. <i>BioDrugs</i> , <b>2019</b> , 33, 635-645	7.9	4
7	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 744-759	2.4	75
6	LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1-8	5.4	
5	[Questionnaire Survey on Adoption and Prescription of Biosimilars (Antibody and Its-related Products) by Medical Doctors in Japan].. <i>Yakugaku Zasshi</i> , <b>2022</b> ,	0	0
4	Targeting ectromelia virus and TNF/NF- $\kappa$ B or STAT3 signaling for effective treatment of viral pneumonia.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	1
3	Patients Retransitioning from Biosimilar TNF Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. <i>BioDrugs</i> , <b>2021</b> , 36, 27	7.9	1
2	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. <i>BioDrugs</i> ,	7.9	0
1	Management of patients with inflammatory rheumatic diseases after treatment failure with a first TNF inhibitor: a narrative review.		0